HK1054200A1 - 芳香酶抑制劑和單克隆抗her2抗體作為抗腫瘤劑 - Google Patents

芳香酶抑制劑和單克隆抗her2抗體作為抗腫瘤劑

Info

Publication number
HK1054200A1
HK1054200A1 HK03106504.3A HK03106504A HK1054200A1 HK 1054200 A1 HK1054200 A1 HK 1054200A1 HK 03106504 A HK03106504 A HK 03106504A HK 1054200 A1 HK1054200 A1 HK 1054200A1
Authority
HK
Hong Kong
Prior art keywords
antitumors
agents
monoclonal anti
aromatase inhibitors
her2 antibodies
Prior art date
Application number
HK03106504.3A
Other languages
English (en)
Chinese (zh)
Inventor
G‧馬斯米尼
G‧皮斯特裡
D‧普蘭達爾
Original Assignee
法瑪西雅意大利公司
法瑪西雅厄普約翰美國公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 法瑪西雅意大利公司, 法瑪西雅厄普約翰美國公司 filed Critical 法瑪西雅意大利公司
Publication of HK1054200A1 publication Critical patent/HK1054200A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK03106504.3A 2000-05-15 2003-09-11 芳香酶抑制劑和單克隆抗her2抗體作為抗腫瘤劑 HK1054200A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US57135500A 2000-05-15 2000-05-15
PCT/EP2001/004468 WO2001087334A1 (fr) 2000-05-15 2001-04-19 Inhibiteurs des aromatases et anticorps monoclonaux anti-her2 utiles en tant qu'agents antitumoraux

Publications (1)

Publication Number Publication Date
HK1054200A1 true HK1054200A1 (zh) 2003-11-21

Family

ID=24283360

Family Applications (1)

Application Number Title Priority Date Filing Date
HK03106504.3A HK1054200A1 (zh) 2000-05-15 2003-09-11 芳香酶抑制劑和單克隆抗her2抗體作為抗腫瘤劑

Country Status (20)

Country Link
EP (1) EP1282440A1 (fr)
JP (1) JP2003533490A (fr)
KR (1) KR20030014223A (fr)
CN (1) CN1429118A (fr)
AU (1) AU784617B2 (fr)
BR (1) BR0110732A (fr)
CA (1) CA2409652A1 (fr)
CZ (1) CZ20023748A3 (fr)
EA (1) EA005931B1 (fr)
EE (1) EE200200622A (fr)
HK (1) HK1054200A1 (fr)
HU (1) HUP0301877A2 (fr)
IL (1) IL152389A0 (fr)
MX (1) MXPA02011194A (fr)
NO (1) NO20025302L (fr)
NZ (1) NZ523004A (fr)
PL (1) PL360153A1 (fr)
SK (1) SK16022002A3 (fr)
WO (1) WO2001087334A1 (fr)
ZA (1) ZA200209815B (fr)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA9811162B (en) 1997-12-12 2000-06-07 Genentech Inc Treatment with anti-ERBB2 antibodies.
AUPQ105799A0 (en) 1999-06-18 1999-07-08 Victor Chang Cardiac Research Institute, The Cell growth inhibition
KR20030007640A (ko) 2000-05-19 2003-01-23 제넨테크, 인크. ＥｒｂＢ 길항제에 의한 암 치료요법에 대한 효과적인반응의 가능성을 개선시키기 위한 유전자 검출 분석
CA2434611A1 (fr) * 2001-01-26 2002-09-19 Pharmacia Italia Spa Procede combine de traitement de troubles hormonodependants
GB2375958B (en) 2001-04-09 2005-03-02 George Margetts The use of steroids to lower the levels of cortisol
JP4660094B2 (ja) 2002-03-26 2011-03-30 ゼンサン （シャンハイ） サイ−テク． リミテッド 新生物を治療するためのＥｒｂＢ３に基づく方法および組成物
BR0312484A (pt) * 2002-07-01 2008-01-08 Savient Pharmaceuticals Inc compostos e métodos para tratamento terapêutico
FR2844455B1 (fr) * 2002-09-13 2007-12-14 Lab Francais Du Fractionnement Traitement des pathologies echappant a la reponse immune par des anticorps optimises
EP2322217A3 (fr) * 2004-07-16 2011-09-28 Pfizer Products Inc. Traitement combiné pour malignités non hematologiques par anticorps anti-IGF-1R
PL1846030T3 (pl) 2005-01-21 2019-05-31 Genentech Inc Ustalone dawkowanie przeciwciał her
NZ590431A (en) 2005-02-23 2012-08-31 Genentech Inc Extending time to disease progression or survival in cancer patients using a HER dimerization inhibitor
CA2626337C (fr) 2005-10-19 2015-12-29 Chavah Pty Ltd Reduction des effets secondaires des inhibiteurs de l'aromatase employes dans le traitement du cancer du sein
MX2009008981A (es) 2007-03-02 2009-09-02 Genentech Inc Prediccion de respuesta a un inhibidor her.
US9551033B2 (en) 2007-06-08 2017-01-24 Genentech, Inc. Gene expression markers of tumor resistance to HER2 inhibitor treatment
SI2171090T1 (sl) 2007-06-08 2013-07-31 Genentech, Inc. Markerji genskega izraĹľanja tumorske odpornosti na HER2 inhibitorsko zdravljenje
BRPI0812682A2 (pt) 2008-06-16 2010-06-22 Genentech Inc tratamento de cáncer de mama metastático
EP2408817B1 (fr) 2009-03-20 2016-03-16 F.Hoffmann-La Roche Ag Anticorps anti-her di-spécifiques
WO2010136569A1 (fr) 2009-05-29 2010-12-02 F. Hoffmann-La Roche Ag Modulateurs de la signalisation her2 chez des patients exprimant her2 souffrant d'un cancer de l'estomac
US9556249B2 (en) 2010-02-18 2017-01-31 Genentech, Inc. Neuregulin antagonists and use thereof in treating cancer
WO2011146568A1 (fr) 2010-05-19 2011-11-24 Genentech, Inc. Prédiction de réponses à un inhibiteur de her
WO2012069466A1 (fr) 2010-11-24 2012-05-31 Novartis Ag Molécules multi-spécifiques
SG191153A1 (en) 2010-12-23 2013-07-31 Hoffmann La Roche Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
CN102068429B (zh) * 2010-12-28 2011-12-14 西南大学 法倔唑在诱导罗非鱼已分化卵巢转变为功能型精巢中的应用及其诱导方法
CA2842375A1 (fr) 2011-08-17 2013-02-21 Erica Jackson Anticorps anti-neureguline et utilisations associees
US9327023B2 (en) 2011-10-25 2016-05-03 The Regents Of The University Of Michigan HER2 targeting agent treatment in non-HER2-amplified cancers having HER2 expressing cancer stem cells
CA2857114A1 (fr) 2011-11-30 2013-06-06 Genentech, Inc. Mutations dans erbb3 dans des cancers
US9376715B2 (en) 2011-12-09 2016-06-28 Roche Molecular Systems, Inc Methods for detecting mutations in the catalytic subunit of the phosphoinositol-3 kinase (PIK3CA) gene
CA2865082A1 (fr) 2012-03-27 2013-10-03 Genentech, Inc. Diagnostic et traitements concernant des inhibiteurs de her3
US20160038490A1 (en) * 2012-07-18 2016-02-11 Angion Biomedica Corp. Compositions and methods for treating dysproliferative diseases
CA2889298C (fr) 2012-11-30 2024-01-02 Anton Belousov Identification de patients ayant besoin d'une cotherapie par un inhibiteur de pd-l1
CA2965372C (fr) 2014-10-22 2023-09-05 Havah Therapeutics Pty Ltd Procede de reduction de densite mammaire monographique et/ou de risque de cancer du sein
CA3002562A1 (fr) 2015-10-22 2017-04-27 Havah Therapeutics Pty Ltd Procedes de reduction de la densite mammaire a la mammographie et/ou du risque de cancer du sein
WO2017194554A1 (fr) 2016-05-10 2017-11-16 Inserm (Institut National De La Sante Et De La Recherche Medicale) Polythérapies pour le traitement du cancer
CN107417791B (zh) * 2017-08-17 2020-09-22 合肥瀚科迈博生物技术有限公司 抗人ErbB2双特异性抗体、其制备方法及用途
EP3976048A4 (fr) 2019-06-03 2023-07-12 Havah Therapeutics Pty Ltd Formulations pharmaceutiques et systèmes pour l'administration d'un agent androgène et d'un inhibiteur de l'aromatase, et procédés d'utilisation

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA9811162B (en) * 1997-12-12 2000-06-07 Genentech Inc Treatment with anti-ERBB2 antibodies.

Also Published As

Publication number Publication date
CN1429118A (zh) 2003-07-09
JP2003533490A (ja) 2003-11-11
CZ20023748A3 (cs) 2003-04-16
MXPA02011194A (es) 2003-03-10
CA2409652A1 (fr) 2001-11-22
AU5630901A (en) 2001-11-26
SK16022002A3 (sk) 2003-04-01
NO20025302D0 (no) 2002-11-05
HUP0301877A2 (hu) 2003-09-29
ZA200209815B (en) 2003-12-03
PL360153A1 (en) 2004-09-06
KR20030014223A (ko) 2003-02-15
NO20025302L (no) 2002-11-05
NZ523004A (en) 2004-09-24
EA200201213A1 (ru) 2003-04-24
EE200200622A (et) 2004-06-15
EP1282440A1 (fr) 2003-02-12
EA005931B1 (ru) 2005-08-25
BR0110732A (pt) 2003-02-04
IL152389A0 (en) 2003-05-29
AU784617B2 (en) 2006-05-18
WO2001087334A1 (fr) 2001-11-22

Similar Documents

Publication Publication Date Title
PL360153A1 (en) Aromatase inhibitors and monoclonal anti-her2 antibodies as antitumors agents
HUP0300841A3 (en) Agonist anti-trk-c monoclonal antibodies
IL158643A (en) Anti-hmg monoclonal antibodies and compositions containing the same
GB0029360D0 (en) Humanised antibodies and uses thereof
IL156030A0 (en) Humanized antibodies
AU1174702A (en) Humanized anti-lt-beta-r antibodies
HK1158219A1 (zh) 細胞亞群特異單克隆和多克隆抗體的組合物和方法
PL354112A1 (en) Application of anti-ctla-4 antibodies
EP1391464A4 (fr) Anticorps monoclonal anti-cd40
HK1153763A1 (en) Anti-her2 antibody variants
IL166244A0 (en) Super humanized antibodies
EP1448601A4 (fr) Methodes et compositions d'anticorps monoclonaux specifiques des proteines beta-amyloides
EP1572077A4 (fr) Utilisations d'anticorps 8h9 monoclonaux
EP1399187A4 (fr) Utilisations d'anticorps monoclonal 8h9
AU2002340167A8 (en) Anti-hla-dr antibodies and the methods of using thereof
AU2001277022A1 (en) Bispecific monoclonal antibodies to il-12 and il-18 receptors
AU2003220079A8 (en) Uses of monoclonal antibody 8h9
EP1178829A4 (fr) Anticorps monoclonal humain
FI20011055A0 (fi) Heveiiniä sitovat monoklonaaliset vasta-aineet
EP1446416A4 (fr) Anticorps monoclonaux specifiques de tumeur
GB0003359D0 (en) Monoclonal antibodies
GB0008160D0 (en) Monoclonal antibodies
GB0029846D0 (en) Monoclonal antibody
GB0030139D0 (en) Monoclonal antibody
GB0020794D0 (en) Humanised antibodies